newsfilter
← Latest News
GlobeNewswire·

Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock

SAN CARLOS, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the pricing of an underwritten